AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Precision BioSciences Inc... (DTIL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

5.90

0.25 (4.42%)

At close: Feb 20, 2025, 3:59 PM

5.89

-0.16%

After-hours: Feb 20, 2025, 06:46 PM EST

undefined% (undefined)

Bid	5.5
Market Cap	46.56M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.4
PE Ratio (ttm)	14.75
Forward PE	n/a
Analyst	Buy

Ask	5.99
Volume	368,429
Avg. Volume (20D)	503,406
Open	5.83
Previous Close	5.65
Day's Range	5.53 - 5.99
52-Week Range	3.61 - 19.43
Beta	undefined

About DTIL

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is i...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 28, 2019

Employees 108

Stock Exchange NASDAQ

Ticker Symbol DTIL

Website https://www.precisionbiosciences.com

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for DTIL stock is "Buy." The 12-month stock price forecast is $34, which is an increase of 476.32% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Precision BioSciences Inc. is scheduled to release its earnings on Mar 26, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 day ago New

+9.71%

Precision Biosciences shares are trading higher af... Unlock content with Pro Subscription

News

1 day ago · benzinga.com

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

On Wednesday, Precision BioSciences, Inc. DTIL revealed initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial.

1 day ago · businesswire.com

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...

3 weeks ago · businesswire.com

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

1 month ago · benzinga.com

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

On Thursday, Precision BioSciences Inc.'s DTIL partner iECURE reported clinical efficacy and safety data in the first patient dosed with ECUR-506 in the Phase 1/2 OTC-HOPE study.

1 month ago · businesswire.com

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

1 month ago · businesswire.com

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion therapies for the treatment of liver disorders with significa...

2 months ago · businesswire.com

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

3 months ago · businesswire.com

Precision BioSciences to Participate in Upcoming November Investor Conferences